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with the AC set up as recommended by the manufacturer. All 
measurements were corrected for daily output variations. 
3DVH software (Sun Nuclear Corporation, Fl, USA) was used 
to create a measurement guided 3D dose estimation in the 
patient's planning CT. Plans were created in Eclipse TPS v11 
using AAA and DVO v11.0.30 and delivered using a Varian 21iX 
linac (Varian Medical Systems, Ca, USA). The plans included 
both 6 and 10 MV photon energies and covered a range of 
treatment sites. 
The measured and planned 2D dose distributions were 
compared using a 2%G/2mm 2D gamma pass rate (GPR). The 
3DVH and TPS 3D dose distributions were compared using a 
2%G/2mm 3D GPR and DVH analysis for the PTV and OARs. 
Results: AC and MC 2D GPRs are equivalent for plans with 
mean field area ≤ 120 cm2 (figure 1). However, after 
processing with 3DVH, calculated 3D GPRs for AC deteriorate 
significantly compared to MC, particularly for 10 MV plans. 
This is caused by the different processes involved in 
converting the AC and MC measurements to 3D dose 
distributions by 3DVH. 
For plans with a mean field area > 120 cm2 the 2D and 3D 
GPRs for AC are significantly worse than for MC. This may be 
due to the obliquity of the fields relative to the diodes at the 
edge of the array leading to shielding and directional 
dependence effects. The AC software does correct for these 
effects but our measurements suggest these corrections are 
not sufficient. Overall, MC based 3D dose estimations are in 
closer agreement with the TPS for all field sizes and 
energies. 
 
Figure 1: 2D and 3D GPR versus mean field area (cm2). 
Table 1 shows that the conversion from 2D to 3D for AC leads 
to reduced GPRs for 10 MV plans. The primary cause of this is 
a difference between the 10 MV 3DVH AC PDDs and the 
measured PDDs. In contrast, the 6 MV 3DVH AC PDDs match 
measured PDDs and the conversion to 3D improved the GPRs 
for 6 MV plans. The difference between 6 and 10 MV 3D dose 
estimation is also evident in the PTV Dmean. 
Table 1: Mean (±s) 2%/2mm GPRs and percentage variation in 





Conclusions: For IMRT QA, ArcCHECK is not an ideal system 
for plans with field area > 120 cm2. For 3D dose estimation 
using 3DVH, the ArcCHECK performed significantly worse for 
10 MV than for 6 MV plans. Overall, we found that the 
MapCHECK2 was more suitable than the ArcCHECK for 3D 
dose estimation using 3DVH. 
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Purpose/Objective: Stereotactic radiosurgery alone has 
become a popular treatment option in the management of 
patients with brain metastases. Multi- or single-isocenter 
dynamic conformal arcs (DCA) and volumetric modulated arc 
therapy (VMAT) are two common used delivery techniques. 
Recently, a dedicated inverse optimized brain metastases 
treatment planning solution using single isocenter multiple 
DCA has been developed, with intend to carefully balance 
normal tissue protection, target coverage and treatment 
speed. The purpose of the current study was to investigate 
the feasibility of this novel software and to benchmark it 
against well-established multi-isocenter DCA and single 
isocenter VMAT approaches. 
Materials and Methods: Ten previously treated patients were 
selected representing a variable number of lesions, range of 
target sizes and shapes most frequently observed in the 
practice of SRS for brain metastases. Number of lesions 
ranged between 1 and 8. The original multi-isocenter DCA 
(MIDCA) treatment plans were replanned with both single-
isocenter VMAT approach and the novel brain metastases tool 
(Elements, Brainlab AG, Germany). The treatment dose was 
20 Gy at the 80% prescription isodose. For all the plans, the 
dose to the surrounding healthy brain tissue (brainstem, 
cochlea, optical nerve, eyes and lens) was optimized to 
minimize normal tissue complications. The plans were 
evaluated by calculation of Paddick conformity and gradient 
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index, and the volume receiving 10 and 12 Gy indicating risk 
of radionecrosis. 
Results: All plans were judged clinically acceptable, but 
differences were observed in the dosimetric parameters. 
MIDCA achieved conformal plans (CI = 0.66 ± 0.07) with steep 
dose fall-off (GI = 4.47 ± 1.57), a V12 of 35.56 ± 26.41 cc and 
a V10 of 49.03 ± 38.10 cc. The VMAT plans had comparable 
conformity (0.67 ± 0.12) than MIDCA, worse GI (7.11 ± 3.12) 
and higher V10 (67.93 ± 55.93 cc) and V12 (46.34 ± 35.92 cc). 
The brain metastases software tool generated plans with 
similar CI (0.65 ± 0.08) then the two established treatment 
techniques while improving the GI (3.94 ± 1.42) and managing 
comparable V10 (48.47 ± 35.93 cc) and V12 (36.30 ± 27.09 cc) 
compared to MIDCA. 
Conclusions: Our results suggest that the automated brain 
metastases planning algorithm can achieve similar conformity 
and low dose spread compared to multi-isocenter DCA while 
increasing efficiency in both treatment planning and delivery 
due to the use of a single-isocenter approach. In terms of 
efficiency, VMAT radiosurgery was already likely to replace 
the multi-isocenter DCA technique for multiple lesions at the 
cost of increased low dose spread. Comparable efficiency was 
found with the new algorithm while improved dose gradient 
was observed suggesting that this novel software offers the 
best of both world (i.e. efficient single-isocenter DCA 
delivery). 
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Purpose/Objective: In our clinic, the treatment technique of 
choice for the majority of patients is Volumetric Arc Therapy. 
At present, paediatric medulloblastoma patients undergoing 
cranial spinal radiotherapy will be offered proton therapy 
elsewhere. Sometimes, due to bad prognoses and physical 
shape of the patient, the patient is treated locally with 
classical 3D-CRT photon fields. Overlapping posterior fields 
induces high dose maximums and the dose distribution will be 
sensitive to patient positioning. Moreover, this technique is 
prone to high heart doses and inhomogeneous target 
coverage. This study compares VMAT plans with classical 3D-
CRT plans while comparing the risk for mortality attributable 
to secondary cancer and heart toxicity using the Life Years 
Lost-principle (LYL1) as well as the risk for hematologic 
effects2. Furthermore, the VMAT plans can be optimized in a 
fashion that the dose distribution will be less sensitive to 
patient positioning and the benefit of such an approach will 
be assessed. 
Materials and Methods: Five patients were treated with the 
3D-CRT cranial spinal technique. On those patients all OAR 
were retrospectively delineated including the bone producing 
bone marrow. The VMAT plans consists of fields that are 
deliberately field overlapping, ranging from 1 to 4 cm. The 
total dose was 36 Gy in 20 fractions. The robustness of the 
dose distribution towards patient positioning errors was 
tested by moving the isocentres in the treatment plan by 5 
mm in the cranial-caudal direction. The LYL estimates were 
calculated and compared for lung and heart. The acute 
haematological toxicity was investigated by calculating the 
V3Gy of the red marrow (trombocytes) and the V2Gy 
(leukocytes), V3Gy (hæmoglobin) to the total body. 
Results: As a result, the dose max for both planning 
techniques changes according to table 1. The LYL for lungs 
increases with a factor 1.5 to 3 and the LYL for myocardial 
infarction decreases with a factor 0.5 to 1.0 when using 
VMAT. The V3Gy of the bone marrow and V3Gy, V2Gy of the body 
increases with a factor 2 when using VMAT. 
Conclusions: The VMAT technique provides a more robust 
dose distribution. The LYL principle can be used as a measure 
to compare plans and to re-optimize the dose distribution. 
The LYL estimates are intrinsically uncertain due to the 
limited knowledge of second cancer dose-response and the 
incidence profile across attained age, and the results should 
be interpreted in this context. The VMAT technique will 
induce a higher risk of acute Anaemia, leukopaenia and 
Thrombocytopaenia, but can be controlled when the patient 
is monitored daily. 
1 Brodin NP et al, Life Years Lost-Comparing potentially fatal 
late complications after radiotherapy for pediatric 
medulloblastoma on a common scale, Cancer, 2012 Nov 
1;118(21):5432-40 
2 Petersson K et al, Haematological toxicity in adult patients 
receiving craniospinal irrdation – indication of a dose-bath 
effect, Radioth and Onc, 2014 Apr;111(1):47-51 
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Purpose/Objective: Varian RapidPlan™ knowledge-based 
planning software is designed to increase consistency and 
improve efficiency in treatment planning. The aim of this 
study was to compare the quality of plans produced using 
RapidPlan with those produced following local standard 
planning procedures for prostate treatments.  
Materials and Methods: A dose prediction model was trained 
using clinical treatment plans for 35 prostate patients 
previously treated with 37 fractions of 5-field IMRT. A high-
dose PTV (prostate + 0.5cm/0cm posterior margin) was 
planned to 78Gy, with additional PTVs treated to 71Gy 
(prostate + 1.0cm/0.6cm) and 60Gy (seminal vesicles + 
1.0cm) using Varian Eclipse v13.5. 10 additional patients 
previously planned using local clinical procedures were then 
replanned using the RapidPlan model to predict DVHs and 
thereby generate patient-specific initial plan optimization 
objectives. Priorities for minimum target dose objectives 
